A drug, known as bremelanotide, which is meant to help women having hypoactive sexual desire disorder (HSDD), is expected to receive FDA approval this week.
Though drug has shown modest effects in increasing women’s sex drive, but still there are still a few researchers who argue that it simply is pharmaceutical science overreach, a new effort which lowers complexities when it comes to human sexuality by quantifiable dots made on a graph.
The manufacturer of bremelanotide, AMAG Pharmaceuticals hopes that the drug could help boost sexual desire among women just like how Viagra helps to deal with erectile dysfunction.
On the other hand, there already exists a marketed drug for HSDD called Addyi, a pill whose 2015-approval by FDA came in with an intense debate on whether sexual desire indeed was a medical problem. Addyi since then has become commercial nonentity, mainly because the women are restrained from having alcohol right before take the pill. But, the debate around the FDA-approval of Addyi faded away with its insubstantial sales.
However bremelanotide, which offers a promise of similar effects with lesser side-effects, has again ignited conversation on whether sexual desire could be a pharmaceutical overreach.
Well, one will have to wait and see what response bremelanotide finally receives.